Format

Send to

Choose Destination
Am J Clin Oncol. 2000 Jun;23(3):319-21.

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.

Author information

1
Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, USA.

Abstract

Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center